GlassScriptPhysician profile
Donna W Kasper
NPI 1568647030
$3,828.99
in general payments reported to CMS, 2019-2025
24 companies · $675 in 2025
The $675 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $1,468 · 2023: $587 · 2024: $716 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,977.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,064.98 | 2022 | |
| Sumitomo Pharma America, INC. | $737.25 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $426.66 | 2021-2024 | Myrbetriq, Xtandi, Veozah |
| Pfizer INC. | $222.29 | 2021-2025 | |
| Myovant Sciences INC. | $164.41 | 2021-2022 | |
| Teleflex LLC | $163.85 | 2023-2024 | Urolift |
| Urogen Pharma, INC. | $163.56 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $135.34 | 2025 | Erleada |
| Janssen Biotech, INC. | $130.08 | 2021-2025 | Erleada |
| Acerus Pharmaceuticals Corporation | $83.38 | 2021-2022 | |
| Allergan, INC. | $82.17 | 2021-2022 | |
| Urovant Sciences INC | $61.93 | 2021-2022 | |
| Boston Scientific Corporation | $57.99 | 2023-2025 | Axonics, Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $50.89 | 2024-2025 | Lynparza |
| Abbvie INC. | $48.24 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $48.20 | 2024 | |
| Tolmar, INC. | $42.04 | 2023-2025 | Eligard, Jatenzo |
| Axonics, INC. | $37.98 | 2023-2024 | Bulkamid |
| Ferring Pharmaceuticals INC. | $24.23 | 2025 | Adstiladrin |
| Halozyme INC | $22.00 | 2023 | |
| Progenics Pharmaceuticals, INC. | $20.97 | 2022 | |
| Endo USA, INC. | $15.74 | 2025 | Xiaflex, Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $12.75 | 2022 | |
| Endo Pharmaceuticals INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.